Correlation Between Kura Oncology and Lyra Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kura Oncology and Lyra Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and Lyra Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kura Oncology and Lyra Therapeutics, you can compare the effects of market volatilities on Kura Oncology and Lyra Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of Lyra Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and Lyra Therapeutics.

Diversification Opportunities for Kura Oncology and Lyra Therapeutics

0.7
  Correlation Coefficient

Poor diversification

The 3 months correlation between Kura and Lyra is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and Lyra Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyra Therapeutics and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with Lyra Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyra Therapeutics has no effect on the direction of Kura Oncology i.e., Kura Oncology and Lyra Therapeutics go up and down completely randomly.

Pair Corralation between Kura Oncology and Lyra Therapeutics

Given the investment horizon of 90 days Kura Oncology is expected to under-perform the Lyra Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Kura Oncology is 1.34 times less risky than Lyra Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The Lyra Therapeutics is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  30.00  in Lyra Therapeutics on November 2, 2024 and sell it today you would lose (12.00) from holding Lyra Therapeutics or give up 40.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Kura Oncology  vs.  Lyra Therapeutics

 Performance 
       Timeline  
Kura Oncology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Kura Oncology and Lyra Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kura Oncology and Lyra Therapeutics

The main advantage of trading using opposite Kura Oncology and Lyra Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, Lyra Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyra Therapeutics will offset losses from the drop in Lyra Therapeutics' long position.
The idea behind Kura Oncology and Lyra Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets